CN119072326A - 用于预防和/或治疗由SARS-CoV-2引起的感染的化合物 - Google Patents

用于预防和/或治疗由SARS-CoV-2引起的感染的化合物 Download PDF

Info

Publication number
CN119072326A
CN119072326A CN202380017328.1A CN202380017328A CN119072326A CN 119072326 A CN119072326 A CN 119072326A CN 202380017328 A CN202380017328 A CN 202380017328A CN 119072326 A CN119072326 A CN 119072326A
Authority
CN
China
Prior art keywords
cov
sars
oph
viral
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380017328.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·拉福吉
P·格雷森斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Western Dais Paris, University of
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Western Dais Paris, University of
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western Dais Paris, University of, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Western Dais Paris, University of
Publication of CN119072326A publication Critical patent/CN119072326A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN202380017328.1A 2022-01-24 2023-01-19 用于预防和/或治疗由SARS-CoV-2引起的感染的化合物 Pending CN119072326A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305072.5 2022-01-24
EP22305072 2022-01-24
PCT/EP2023/051296 WO2023139182A1 (en) 2022-01-24 2023-01-19 Compound for use in preventing and/or treating an infection caused by sars-cov-2

Publications (1)

Publication Number Publication Date
CN119072326A true CN119072326A (zh) 2024-12-03

Family

ID=80446266

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380017328.1A Pending CN119072326A (zh) 2022-01-24 2023-01-19 用于预防和/或治疗由SARS-CoV-2引起的感染的化合物

Country Status (6)

Country Link
US (1) US20250099530A1 (https=)
EP (1) EP4469073A1 (https=)
JP (1) JP2025504519A (https=)
KR (1) KR20240139056A (https=)
CN (1) CN119072326A (https=)
WO (1) WO2023139182A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2923160B1 (fr) 2007-11-02 2013-07-26 Pasteur Institut Composes destines a prevenir ou traiter une infection virale.
WO2021228846A1 (en) 2020-05-11 2021-11-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compound for preventing or treating a viral infection
WO2022008597A1 (en) * 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2022123062A1 (en) * 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients

Also Published As

Publication number Publication date
EP4469073A1 (en) 2024-12-04
WO2023139182A1 (en) 2023-07-27
JP2025504519A (ja) 2025-02-12
US20250099530A1 (en) 2025-03-27
KR20240139056A (ko) 2024-09-20

Similar Documents

Publication Publication Date Title
AU2021228008B2 (en) Use of nucleoside compound in treatment of coronavirus infectious diseases
Li et al. Antiviral activity of arbidol hydrochloride against herpes simplex virus I in vitro and in vivo
US11730723B2 (en) Compounds and methods for treating viral infections
JP2017512837A (ja) ウイルス感染の治療または予防における使用のためのｒｎアーゼ
US7491489B2 (en) Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
US8729059B2 (en) Paramyxovirus family inhibitors and methods of use thereof
US11666575B2 (en) Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections
CN119072326A (zh) 用于预防和/或治疗由SARS-CoV-2引起的感染的化合物
US20240100150A1 (en) Reverse genetics-based compositions of recombinant sars-cov-2
ES2670713T3 (es) Virus sincitial respiratorio con una deficiencia genómica complementada en trans
KR20230121767A (ko) Covid-19의 예방 및 치료를 위한 디펜히드라민 및 락토페린
TWI799923B (zh) 硫代咪唑烷酮藥物在治療covid-19疾病中的用途
AU2017210921B2 (en) Composition and combined medication method for treating enterovirus infection
TWI917417B (zh) 治療病毒感染之方法及組合物
US20240307525A1 (en) Reverse genetics-based compositions of attenuated recombinant sars-cov-2
TWI764284B (zh) 使用喹啉化合物來對抗冠狀病毒感染的方法
JP2025534078A (ja) ナファモスタットとｋ７７７を含む医薬組み合わせ及びその使用
Parveen et al. Respiratory syncytial virus (RSV): prevention and antiviral therapeutic strategies
CN118286436A (zh) Iii型磷脂酰肌醇3-激酶抑制剂在制备抑制肠道病毒药物中的应用
HK40077240A (en) Aak1 inhibitors for use in treating viral infections
Boczkowska Aspects of porcine immunological response to Nipah virus
EA050990B1 (ru) Применение нуклеозидного соединения при лечении коронавирусных инфекционных заболеваний
HK40076317A (en) 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
Del Vecchio et al. Cold Virus Fusion or Stopping Fusion Cold-Inhibitors of the Human Respiratory Syncytial Virus F Protein
de Almeida Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado–Joseph disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination